Altimmune
ALT
71 hedge funds and large institutions have $20.3M invested in Altimmune in 2017 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 26 increasing their positions, 20 reducing their positions, and 23 closing their positions.
30% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 20
19% less funds holding
Funds holding: 88 → 71 (-17)
57% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 23
77% less capital invested
Capital invested by funds: $90.1M → $20.3M (-$69.8M)
98% less call options, than puts
Call options by funds: $3K | Put options by funds: $146K
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| 1 |
BlackRock
New York
|
+$4.92M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.36M |
| 3 |
FQ
First Quadrant
Glendale,
California
|
+$2.9M |
| 4 |
Renaissance Technologies
New York
|
+$2.57M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.52M |
Top Sellers
ALT Hedge Fund Activity: Q1 2017 in Review
71 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q1 2017, worth a combined $20.3M — down 77% from $90.1M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ALT and 10 opened new positions — a net loss of 13 holders — while 20 trimmed existing stakes and 26 added.
The largest buyer was BlackRock, adding an estimated $4.92M. The largest seller was Prescott Group Capital Management, exiting entirely with an estimated $10.6M sold.
- 71 institutional investors held Altimmune (ALT) as of Q1 2017, down from 88 in Q4 2016.
- Funds reported $20.3M of Altimmune stock for Q1 2017, down 77% quarter-over-quarter.
- 10 funds opened new Altimmune positions in Q1 2017 and 23 closed out, a net change of -13 holders.
- The largest Altimmune buyer in Q1 2017 was BlackRock, an estimated $4.92M added.
- The largest Altimmune seller in Q1 2017 was Prescott Group Capital Management, an estimated $10.6M sold.
Based on aggregated 13F filings for Q1 2017.